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Introduction
Axillary nodal involvement is an essential prognostic factor in
patients with breast cancer. The presence of positive axillary
lymph nodes implies the need for systemic adjuvant chemo-
therapy and locoregional irradiation. Hence, axillary lymph
node dissection (ALND) contributes to accurate staging of the
disease and also, to an extent, confers improved local disease
control.1 However, ALND carries a 10–25% incidence of early
and late morbidity,1 including temporary shoulder stiffness,
sensory loss in the periaxillary skin and ipsilateral arm
lymphoedema. This oedema is significant from both cosmetic
and comfort standpoints in approximately 5–10% of patients.
Correlation Between Breast Tumour Size and Level of
Axillary Lymph Node Involvement
With increased public awareness and the introduction of
screening breast mammography, diagnoses of breast cancer
are now made at an earlier stage and often when axillary nodes
are free of cancer. For patients with T1 breast cancers (< 2 cm),
there is a relatively low incidence (6–30%) of axillary metasta-
ses.2 The incidence of axillary lymph node metastases increases
as a function of primary tumour size.3 The characteristics of
the primary breast cancer closely associated with axillary
lymph node metastases are tumour size, tumour grade and
lymphovascular invasion,3–5 but only tumour size can be de-
termined preoperatively.
The aim of our study was to determine whether tumour
size influenced the extent of axillary lymph node involvement
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and whether, based on preoperative determination of size,
level I ALND would be adequate for small tumours (< 2 cm).
Patients and methods
Data were collected prospectively for patients undergoing
breast cancer surgery at the Department of General Surgery,
Singapore General Hospital, and the Department of Surgical
Oncology, National Cancer Centre, between May and Decem-
ber 2002. All patients with palpable tumours underwent
preoperative ultrasound to objectively determine the size of
the primary breast lesion. The ultrasound probe used was a
7.5 MHz linear array probe.
Standard level I/II ALND was performed for all patients
and the different levels were sent for analysis separately. Axil-
lary levels (I, II and III) were determined according to the
relationship of axillary tissue to the pectoralis minor muscle:
level I was lateral to the muscle, level II inferior to the muscle
and level III medial to the muscle. These axillary levels were
determined intraoperatively with the arm positioned at 90$ to
the body.
The pathologists were requested to review the total number
of lymph nodes and the number of involved lymph nodes at
each separate axillary level instead of providing a cumulative
result of all levels. Standard haematoxylin and eosin stain was
used and lymph nodes were serially sectioned at 4 +m thick-
ness for histological evaluation. The staging system used was
the 1997 TNM/American Joint Committee on Cancer system.
T1 tumours were further subclassified into T1a (< 5 mm), T1b
(6–10 mm) and T1c (11–20 mm).
The correlation between primary tumour size and the
extent of level I and II axillary lymph node involvement was
then studied.
Results
In this 6-month period, 202 patients underwent breast cancer
surgery. One patient had bilateral mastectomies simultane-
ously, so we studied a total of 203 breasts. The mean age of
these patients was 53.7 years (range, 29–84 years) and 67% were
postmenopausal. The number of patients by stage of disease is
shown in Table 1. Most patients (88.2%) had infiltrative ductal
carcinoma, followed by infiltrative lobular carcinoma (5.4%).
The greater the T stage, the higher the incidence of level I
lymph node involvement (14.2% in T1, 36.7% in T2 and 46.2%
in T3 tumours) (Table 2). Both level I and II lymph node
involvement was also correspondingly higher for greater T
stage (4.4% in T1, 7.1% in T2 and 36.5% in T3 tumours). Only
one patient had a T4 tumour and she did not have axillary
metastases despite the size of tumour. No node-positive pa-
tients had isolated level II lymph node involvement, which
implied that there were no skip metastases in our series.
The incidence of level II lymph node involvement in T1
cancers was 4.4% (4/91 patients). Review of the details of the
histology in these four patients showed that all had T1c
tumours, two of which were of high grade and the other two
demonstrated lymphovascular invasion. This concurred with
results of other studies emphasizing the importance of exam-
ining primary tumour characteristics, especially when the
primary tumour alone has been excised during a preceding
excision biopsy.3–5
Using the Pearson Correlation test, we found that pre-
operative ultrasonographic-determined tumour size was simi-
lar to the final histopathological T stage (p < 0.0005), which
implies that ultrasound was a good tool to objectively measure
tumour size prior to surgery.
Seventeen patients had no palpable lesions but had abnor-
mal screening mammograms and/or ultrasound findings. Of
these, 70.6% (12/17) had T1 cancers (5 T1a, 2 T1b and 5 T1c
tumours), while the remaining five had T2 cancers. Two of
these 17 patients (11.8%) had level I lymph node involvement
Table 1. Distribution of cases by stage (n = 203)
Stage n (%)
T1 91 (44.8)
   T1a 11 (12.1)
   T1b 21 (23.1)
   T1c 59 (64.8)
T2 98 (48.3)
T3 13 (6.4)
T4 11 (0.5)
T1a = 5 mm or less; T1b = 6–10 mm; T1c = 11–20 mm.
Table 2. Correlation between size and lymph node level
involvement
T No LN Level I LN Level I/II LN n
T1a 11 10 0 11
T1b 20 11 0 21
T1c 42 13 4 59
T2 55 36 7 98
T3 12 16 5 13
T4 11 0 0 11
LN = lymph node involvement.
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only (1 with a T1c tumour and 1 with a T2 tumour). None had
both level I and II lymph node involvement. This is particular-
ly encouraging, as it shows that screening can detect breast
cancer in its earliest stages when the axillary lymph nodes are
free of metastases.
Discussion
Sentinel lymph node biopsy (SLNB) has been used widely to
address the problem of clinically node-negative axillae in small
breast tumours (T1, T2).6,7 The accuracy of SLNB has been
quoted to be as high as 96.9%,8 with a false-negative rate of less
than 10%.9,10 However, a major drawback in the use of SLNB
is the frequent discrepancy between the findings on frozen
section and subsequent paraffin results.11 Such discrepan-
cies would mean that patients with negative findings on
intraoperative examination of frozen sections of the sentinel
node and positive findings on final pathology will undergo
delayed axillary dissection, which would be psychologically
damaging to the patient as well as delay the subsequent adju-
vant therapy required.
We found that the larger the tumour, the higher the inci-
dence of level I as well as level I/II lymph node involvement. Of
patients with T1 tumours, 95.6% did not have level II lymph
node metastases, hence level I clearance would suffice. The
sensitivity of lymph node metastasis detection is equal to, if
not better than, SLNB as all the lymph nodes harvested are
studied on paraffin sections. Level I ALND negates the possi-
bility of having to return to the axilla to perform standard
ALND should the sentinel node be falsely negative. As less
lymphatic drainage is disrupted in level I axillary clearance,
this may cause less arm lymphoedema than standard ALND,
although no prospective randomized studies have proven this
observation.
Most medical oncology units worldwide now advocate
adjuvant chemotherapy for T1c breast cancers, and this may
be sufficient to treat the small percentage (< 5%) of axillary
lymph nodes missed if only level I clearance is used for T1
breast lesions.
Tumour size determined by ultrasound correlates well
with final histological size, and this is particularly useful in
hospitals without radionuclear medicine expertise for sentinel
lymph node imaging.
In conclusion, preoperative determination of tumour size
with ultrasound correlates well with the actual level of axillary
lymph node involvement. Therefore, tumour size can be used
to guide the surgeon to more limited axillary dissection as an
alternative to SLNB for T1 breast cancers.
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